HUA MEDICINE-B 02552Hong Kong Stock Exchange

2.1102.76%( -0.060 )
Oct 13 · End-of-day data, not live · Hong Kong Stock Exchange
HUA MEDICINE-B (02552) Company Profile - Company Info, Industry & Management - cibo

Company Information

Market
HKEX Main Board
Listing Date
2018-09-14
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
KYG4644K1022

Industry

Innovative Drugs & Biologics 1.67%
124 stocks in this industry
Down 80 Up 33
Industry RankingsValue (HKD)Rank
Revenue (Last FY)577.92M68/112
Net Profit (Last FY)1.30B17/125
ROE (Last FY)109.93%1/117

Change is the 2026-10-13 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
Li CHEN Executive Director
George Chien Cheng LIN Executive Director
Yi ZHANG Executive Director
Robert Taylor NELSEN Non-Executive Director
William Robert KELLER Independent Non-Executive Director
Yiu Wa Alec TSUI Independent Non-Executive Director
Yiu Leung Andy CHEUNG Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-06-25.

About this page

This page shows HUA MEDICINE-B (02552) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.